Rasi Gianmarco, Emili Elena, Conway Jessica M, Cotugno Nicola, Palma Paolo
Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Italy.
PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome "Tor Vergata", 00133, Rome, Italy.
NPJ Syst Biol Appl. 2025 Jun 12;11(1):64. doi: 10.1038/s41540-025-00538-6.
Combination antiretroviral therapy controls human immunodeficiency virus-1 (HIV) but cannot eradicate latent proviruses in immune cells, which reactivate upon treatment interruption. Anti-latency therapies like "shock-and-kill" are being developed but are yet to succeed due to the complexity of latency mechanisms. This review discusses recent advances in understanding HIV latency via mathematical modeling, covering key regulatory factors and models to predict latency reversal, highlighting gaps to guide future therapeutic approaches.
联合抗逆转录病毒疗法可控制人类免疫缺陷病毒1型（HIV），但无法根除免疫细胞中的潜伏前病毒，这些潜伏前病毒在治疗中断时会重新激活。诸如“激活并清除”之类的抗潜伏疗法正在研发中，但由于潜伏机制的复杂性，尚未取得成功。本综述讨论了通过数学建模在理解HIV潜伏方面的最新进展，涵盖了关键调控因子以及预测潜伏逆转的模型，强调了有待填补的空白，以指导未来的治疗方法。
